B cell

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Retrieved on: 
Wednesday, August 10, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, FDA, U.S. Securities and Exchange Commission, DLBCL, Survival, Biomarker, Follicular lymphoma, Cell, Non-Hodgkin lymphoma, Hematology, Population, Cytokine release syndrome, Technology, Private Securities Litigation Reform Act, SEC, Cancer, Facebook, B-cell lymphoma, Mantle cell lymphoma, Neutropenia, B cell, Clinical trial, ADCC, Security (finance), Rituximab, Lymphatic system, Patient, Instagram, NHL, COVID-19, Twitter, Bone marrow, Therapy, Safety, Febrile neutropenia, Diffuse large B-cell lymphoma, Risk, Phenotype, Anemia, Immunotherapy, University of Minnesota, Hypertension, Multiple myeloma, University, NAM, LinkedIn, Toxic epidermal necrolysis, Thrombocytopenia, Pharmaceutical industry, Vaccine, Medical device, NK, EU

The study will include patients who have relapsed or refractory lymphoma after at least two prior treatments, which may include CAR-T or stem cell transplant.

Key Points: 
  • The study will include patients who have relapsed or refractory lymphoma after at least two prior treatments, which may include CAR-T or stem cell transplant.
  • Gamida Cell applied the capabilities of its NAM-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy candidate for the treatment of hematologic and solid tumors in combination with standard-of-care antibody therapies.
  • GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

Retrieved on: 
Tuesday, August 9, 2022
Transfer, Graft-versus-host disease, IPSC, U.S. Securities and Exchange Commission, CAR, Risk, Acute lymphoblastic leukemia, CD19, Spleen, GLOBE, Neoplasm, CA, Leukemia, Private Securities Litigation Reform Act, Cancer, B cell, Patent, B-cell lymphoma, TCR, NK, List of Nature Research journals, Potency (pharmacology), Canadian Aviation Regulations, Memorial Sloan Kettering Cancer Center, Security (finance), MSK, Method, Acute leukemia, Blood, T, Chronic lymphocytic leukemia, Patient, Therapy, Bone marrow, Company, Center, SAN, Acquisition, Gene expression, Safety, TRAC, NASDAQ, CRISPR, Phenotype, Maintenance, Immunotherapy, Head, Cell engineering, Lymphoid leukemia, Destiny, Vaccine

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced the publication of preclinical study results demonstrating the successful generation, durable anti-tumor response, and functional persistence of TCR-CAR+ iPSC-derived CD8αβ T cells from induced pluripotent stem cells (iPSCs). The CD8αβ T cells were derived from a single engineered iPSC integrating a novel chimeric antigen receptor (CAR) transgene into the T-cell receptor alpha constant (TRAC) locus, ensuring complete bi-allelic disruption of T-cell receptor (TCR) expression and promoting uniform CAR expression. The discoveries were made under a multi-year research collaboration between the Company and Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering and Head, Gene Expression and Gene Transfer Laboratory, and were published this week in Nature Biomedical Engineering.

Key Points: 
  • The mass production of TCR-CAR+ CD8 T cells from master engineered iPSC lines is a promising approach for development of off-the-shelf, cell-based cancer immunotherapies.
  • Subsequent stimulation of the CAR matured the double-positive population into single-positive CD8 T cells with a phenotype highly correlated with peripheral blood CD8 effector T cells and distinct from T cells and natural killer cells.
  • 10,370,452, which covers compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell including an iPSC.
  • Fate Therapeutics haslicensedintellectual propertyfrom MSK on which Dr. Sadelain is aninventor.As a result of the licensing arrangement, MSK has financial interests related to Fate Therapeutics.

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Retrieved on: 
Tuesday, August 9, 2022
MSD, CNS, GLOBE, B cell, Discovery, GPR6, Patient, Central nervous system, Therapy, Neurodegeneration, Biology, Neuroscience, Protein, Merck & Co., Pharmaceutical industry, Merck, Cerev Del

BOSTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration.

Key Points: 
  • Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration.
  • We believe we are well-positioned to identify novel targets for neurodegenerative diseases and look forward to collaborating with Merck to potentially bring forward transformative therapeutics for patients with Alzheimers disease.
  • We look forward to advancing the discovery program as well as taking advantage of the NETSseq platform to identify new targets with the team at Cerevance.
  • As a result, Cerevances platform can reveal novel therapeutic targets that can be modulated to correct neural circuitry or slow the disease process.

Stem Cell Therapy Global Market Report 2022: Rapid Growth in Emerging Markets & An Increase in Investments in Cell and Gene Therapies Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022
Health, Stem Cells, Lists of diseases, Injury, Population, Growth, Investment, B cell, Hospital, Prevalence, Potency (pharmacology), Research, Degenerative disease, Stem cell, Conditional sentence, Ageing, CAGR, Lists of countries and territories, Adult, Healthcare, Cancer

The global stem cell therapy market reached a value of nearly $4,019.6 million in 2021, having increased at a compound annual growth rate (CAGR) of 70.9% since 2016.

Key Points: 
  • The global stem cell therapy market reached a value of nearly $4,019.6 million in 2021, having increased at a compound annual growth rate (CAGR) of 70.9% since 2016.
  • The stem cell therapy market is segmented by type into allogeneic stem cell therapy and autologous stem cell therapy.
  • The autologous stem cell therapy segment was the largest segment of the stem cell therapy market segmented by type, accounting for 100% of the total in 2021.
  • The stem cell therapy market is also segmented by cell source into adult stem cells, induced pluripotent stem cells, and embryonic stem cells.

Appia Bio Appoints Margo Roberts, Ph.D. to its Board of Directors and Names Jason Damiano, Ph.D. as Chief Scientific Officer

Retrieved on: 
Tuesday, August 9, 2022
Apoptosis, Stem cell, Multimedia, CAR, University, Drug discovery, ACUA, Inflammation, Industry, Technology, UNITY, UCLA, Cancer, B cell, Leadership, TCR, IND, United States Air Force Scientific Advisory Board, Research, LOS, Unity Biotechnology, Biomedical Research, Gilead Sciences, Patient, Pharmacology, Doctor of Philosophy, Biotechnology, Kite Pharma, Therapy, Allotransplantation, Chiron, CSO, Biology, Health, Kite, Novartis Institute for Tropical Diseases, Pharmaceutical industry, Vaccine

LOS ANGELES, Aug. 9, 2022 /PRNewswire/ -- Appia Bio, Inc., a preclinical-stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced the appointment of Margo Roberts, Ph.D. to its board of directors and Jason Damiano, Ph.D. as chief scientific officer (CSO). Dr. Roberts brings three decades of biotech and academic immunology experience, having led early development and application of chimeric antigen receptor (CAR) technology to T cells and stem cells, advancing the first CAR T cells into clinical trials. Dr. Damiano brings research experience in cancer biology, inflammation, new target identification, and drug discovery. He has led numerous therapeutic projects from concept through preclinical development and investigational new drug (IND) application filings.

Key Points: 
  • He has led numerous therapeutic projects from concept through preclinical development and investigational new drug (IND) application filings.
  • Margo is one of the world's foremost experts in immuno-oncology and cell therapy research, and she has seen cell therapy from concept to commercialization.
  • "I have been impressed by Jason in our time working together at UNITY and I anticipate his contributions and leadership will have a great impact at Appia Bio."
  • Dr. Damiano joins Appia Bio from UNITY Biotechnology where he was vice president of biology, advancing a diverse portfolio of programs across multiple disease areas.

Study Using NanoString’s GeoMx Digital Spatial Profiler Featured on the Cover of Nature Genetics

Retrieved on: 
Tuesday, August 9, 2022
Research, Technology, Genetics, Other Technology, Health Technology, Software, Biotechnology, Health, Science, Oncology, U.S. Securities and Exchange Commission, Multimedia, Energy Independence and Security Act of 2007, Hospital, Gene, Cancer, NanoString Technologies, Neoplasm, Assistant, MicroRNA, Technology, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, B cell, Radiation therapy, Malignancy, Massachusetts General Hospital, Research, Security (finance), Department, Marketing, Patient, COVID-19, DSP, Center, Pancreatic cancer, Harvard Medical School, RNA, WTA, Tumor microenvironment, Architecture, Nature Genetics, PDAC, NASDAQ, Biology, Securities Act of 1933, News, Protein, Medical imaging

This paper, along with a tissue image generated using the GeoMx Digital Spatial Profiler (DSP), is featured on the cover of the August 2022 edition of Nature Genetics.

Key Points: 
  • This paper, along with a tissue image generated using the GeoMx Digital Spatial Profiler (DSP), is featured on the cover of the August 2022 edition of Nature Genetics.
  • View the full release here: https://www.businesswire.com/news/home/20220809005149/en/
    A tissue image generated using NanoString's GeoMx Digital Spatial Profiler (DSP) is on the cover of Nature Genetics.
  • The snRNA-seq cell type signatures were used to deconvolve the GeoMx spatial profiles, demonstrating the complementarity of the two platforms.
  • NanoStrings GeoMx Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in more than 100 peer-reviewed publications.

Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 8, 2022
SRS, Survival, GLOBE, R, CSU, Clinical trial, Cancer, Cold urticaria, Knowledge, Research, Patient, Pembrolizumab, Skin, G&A, Loss, Immune system, EAACI, EOE, Private Securities Litigation Reform Act, Hector Avalos, Eosinophilic esophagitis, Allergy, B cell, Form 10-K, Rockefeller University, Biotechnology, Contingency (philosophy), UAS7, Ovarian cancer, Omalizumab, Intellectual property, Term sheet, Forward-looking statement, European Academy of Management, CD27, Hypersensitivity, Itchy, Gilead Sciences, Therapy, COVID-19, Cell, Large-cell lung carcinoma, D, Judgement, SCCHN, Â, Goal, Time, Annual report, SD, Antibody, KIT, Inflammation, Metabolic pathway, Prurigo nodularis, CD40, Hives, European Academy of Allergy and Clinical Immunology, Company, Risk, NASDAQ, Consultant, Pharmaceutical industry, Vaccine, Aluminium, Palladium

HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • In June 2022, Cheryl L. Cohen and Dr. Garry Neil were appointed to the Celldex Board of Directors.
  • The decrease was primarily driven by second quarter cash used in operating activities of $22.2 million.

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Retrieved on: 
Monday, August 8, 2022
People, U.S. Securities and Exchange Commission, Respiration (physiology), GLOBE, Caudate nucleus, SEC, Cancer, Brain, Behavior, Security (finance), Research, HD, Journal of Neuroinflammation, Diffuse axonal injury, Patient, Tumor microenvironment, Astrocyte, Neurodegeneration, Nature Medicine, Microfilament, Immunosuppression, Health, Disease, Government budget balance, HIV disease progression rates, Inflammation, Neuron, Immunoglobulin G, SEMA4D, Kaufman Assessment Battery for Children, Key finding attacks, Apathy, Nasdaq, Locomotion, Forward-looking statement, Microglia, SIGNAL, Caregiver, Neoplasm, Cell, COVID-19, Program, Mutation, Dementia, Atrophy, Cognition, B cell, FDG-PET, Company, Problem solving, Pharmaceutical industry, Medical imaging, Vaccine, Risk management, Journal

ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer’s disease (AD).

Key Points: 
  • These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD.
  • Accordingly, a phase 1b/2a study of pepinemab in Alzheimers disease has been initiated and is actively enrolling patients (NCT04381468).
  • The mechanism of action of pepinemab, targeting neuroinflammation2, may provide an alternative to other AD therapies that target aggregates of A amyloid.
  • The Nature Medicine publication is available online at https://www.nature.com/articles/s41591-022-01919-8 and Journal of Neuroinflammation at https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-022... ; both articles will also be posted on the Vaccinex website.

EV Industry Chain in Kaohsiung Achieves Greater Global Presence

Retrieved on: 
Monday, August 8, 2022
Automotive, Automotive Manufacturing, EV, Electric Vehicles, Transport, Manufacturing, Alternative Vehicles, Fuels, Public Transport, Ministry of Transportation and Communications (Taiwan), Multimedia, Kaohsiung, Technology, Kaohsiung City Government, Investment, Local, Communication, Research, Compliance, Cell, EVS, B cell, Transport, Ministry, EV, Lidar, Lithium, Electricity, City, Foxconn

To forge Kaohsiung an important base for the global EV industry, the Kaohsiung City Government teamed up with Hon Hai Technology Group (Foxconn) to work on several aspects such as smart electric buses and smart city development, with an aim of becoming an experimental field that offers comprehensive business and service model to attract global manufacturers to invest in Kaohsiung and establish a complete industry chain for the EV industry.

Key Points: 
  • To forge Kaohsiung an important base for the global EV industry, the Kaohsiung City Government teamed up with Hon Hai Technology Group (Foxconn) to work on several aspects such as smart electric buses and smart city development, with an aim of becoming an experimental field that offers comprehensive business and service model to attract global manufacturers to invest in Kaohsiung and establish a complete industry chain for the EV industry.
  • View the full release here: https://www.businesswire.com/news/home/20220807005043/en/
    In line with the Kaohsiung City Governments plan to have all public buses run on electricity by 2030, Foxtron Vehicle Technologies delivered the first Model T electric bus to Kaohsiung Bus.
  • In addition, Kaohsiung has also attracted investments from companies such as WIN Semiconductors Corp., the worlds leading foundry for power amplifiers and LiDAR technology for EVs, and lithium battery manufacturer Molie Quantum Energy Corp, laying the groundwork for the EV industry chain.
  • The goal is to shape Kaohsiung into a model smart city and become an example for package smart city export.

Synthetic Biology Market Global Outlook and Forecast 2022-2027: Significant Rise in Investments Fueling Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Health, Biotechnology, Synthetic biology, B cell, Carbon, Technology, Investment, Knowledge, Enzyme, DNA, Engineering, Polymer, Bioproducts, Biotechnology, CAGR, Nature, Biology, Science, Genetics, Pigment, Fine chemical

The "Synthetic Biology Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Synthetic Biology Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global synthetic biology market is expected to grow at a CAGR of 25% during 2022-2027.
  • Synthetic biology is a new interdisciplinary field that includes the application of engineering principles to biology.
  • The synthetic biology market is witnessing a significant rise in investments.